Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeuti...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-06-01
|
| Series: | Molecular Therapy: Oncolytics |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770518300044 |
| _version_ | 1818410266958757888 |
|---|---|
| author | Nicola E. Annels Mehreen Arif Guy R. Simpson Mick Denyer Carla Moller-Levet David Mansfield Rachel Butler Darren Shafren Gough Au Margaret Knowles Kevin Harrington Richard Vile Alan Melcher Hardev Pandha |
| author_facet | Nicola E. Annels Mehreen Arif Guy R. Simpson Mick Denyer Carla Moller-Levet David Mansfield Rachel Butler Darren Shafren Gough Au Margaret Knowles Kevin Harrington Richard Vile Alan Melcher Hardev Pandha |
| author_sort | Nicola E. Annels |
| collection | DOAJ |
| description | As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeutic virus. This study investigated CVA21-induced cytotoxicity in a panel of human bladder cancer cell lines, revealing a range of sensitivities largely correlating with expression of the viral receptor ICAM-1. CVA21 in combination with low doses of mitomycin-C enhanced CVA21 viral replication and oncolysis by increasing surface expression levels of ICAM-1. This was further confirmed using 300-μm precision slices of NMIBC where levels of virus protein expression and induction of apoptosis were enhanced with prior exposure to mitomycin-C. Given the importance of the immunogenicity of dying cancer cells for triggering tumor-specific responses and long-term therapeutic success, the ability of CVA21 to induce immunogenic cell death was investigated. CVA21 induced immunogenic apoptosis in bladder cancer cell lines, as evidenced by expression of the immunogenic cell death (ICD) determinant calreticulin, and HMGB-1 release and the ability to reject MB49 tumors in syngeneic mice after vaccination with MB49 cells undergoing CVA21 induced ICD. Such CVA21 immunotherapy could offer a potentially less toxic, more effective option for the treatment of bladder cancer. Keywords: bladder cancer, coxsackievirus A21, intercellular adhesion molecule-1 |
| first_indexed | 2024-12-14T10:12:48Z |
| format | Article |
| id | doaj.art-547e325fd60c43019bb01a1537f873cb |
| institution | Directory Open Access Journal |
| issn | 2372-7705 |
| language | English |
| last_indexed | 2024-12-14T10:12:48Z |
| publishDate | 2018-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncolytics |
| spelling | doaj.art-547e325fd60c43019bb01a1537f873cb2022-12-21T23:06:57ZengElsevierMolecular Therapy: Oncolytics2372-77052018-06-019112Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E. Annels0Mehreen Arif1Guy R. Simpson2Mick Denyer3Carla Moller-Levet4David Mansfield5Rachel Butler6Darren Shafren7Gough Au8Margaret Knowles9Kevin Harrington10Richard Vile11Alan Melcher12Hardev Pandha13Department of Clinical and Experimental Medicine, Faculty of Health and Medical Science, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UKDepartment of Clinical and Experimental Medicine, Faculty of Health and Medical Science, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UKDepartment of Clinical and Experimental Medicine, Faculty of Health and Medical Science, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UKDepartment of Clinical and Experimental Medicine, Faculty of Health and Medical Science, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UKDepartment of Clinical and Experimental Medicine, Faculty of Health and Medical Science, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UKThe Institute of Cancer Research, London SM2 5PT, UKDepartment of Clinical and Experimental Medicine, Faculty of Health and Medical Science, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UKViralytics Limited, Suite 305, Level 3, 66 Hunter Street, Sydney, NSW 2000, AustraliaViralytics Limited, Suite 305, Level 3, 66 Hunter Street, Sydney, NSW 2000, AustraliaSection of Experimental Oncology, Leeds Institute of Cancer and Pathology, St. James’s University Hospital, Beckett Street, Leeds LS9 7TF, UKThe Institute of Cancer Research, London SM2 5PT, UKDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55902, USAThe Institute of Cancer Research, London SM2 5PT, UKDepartment of Clinical and Experimental Medicine, Faculty of Health and Medical Science, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UK; Corresponding author: Hardev Pandha, Department of Clinical and Experimental Medicine, Faculty of Health and Medical Science, Leggett Building, Daphne Jackson Road, University of Surrey, Guildford GU2 7WG, UK.As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeutic virus. This study investigated CVA21-induced cytotoxicity in a panel of human bladder cancer cell lines, revealing a range of sensitivities largely correlating with expression of the viral receptor ICAM-1. CVA21 in combination with low doses of mitomycin-C enhanced CVA21 viral replication and oncolysis by increasing surface expression levels of ICAM-1. This was further confirmed using 300-μm precision slices of NMIBC where levels of virus protein expression and induction of apoptosis were enhanced with prior exposure to mitomycin-C. Given the importance of the immunogenicity of dying cancer cells for triggering tumor-specific responses and long-term therapeutic success, the ability of CVA21 to induce immunogenic cell death was investigated. CVA21 induced immunogenic apoptosis in bladder cancer cell lines, as evidenced by expression of the immunogenic cell death (ICD) determinant calreticulin, and HMGB-1 release and the ability to reject MB49 tumors in syngeneic mice after vaccination with MB49 cells undergoing CVA21 induced ICD. Such CVA21 immunotherapy could offer a potentially less toxic, more effective option for the treatment of bladder cancer. Keywords: bladder cancer, coxsackievirus A21, intercellular adhesion molecule-1http://www.sciencedirect.com/science/article/pii/S2372770518300044 |
| spellingShingle | Nicola E. Annels Mehreen Arif Guy R. Simpson Mick Denyer Carla Moller-Levet David Mansfield Rachel Butler Darren Shafren Gough Au Margaret Knowles Kevin Harrington Richard Vile Alan Melcher Hardev Pandha Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus Molecular Therapy: Oncolytics |
| title | Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus |
| title_full | Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus |
| title_fullStr | Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus |
| title_full_unstemmed | Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus |
| title_short | Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus |
| title_sort | oncolytic immunotherapy for bladder cancer using coxsackie a21 virus |
| url | http://www.sciencedirect.com/science/article/pii/S2372770518300044 |
| work_keys_str_mv | AT nicolaeannels oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT mehreenarif oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT guyrsimpson oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT mickdenyer oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT carlamollerlevet oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT davidmansfield oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT rachelbutler oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT darrenshafren oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT goughau oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT margaretknowles oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT kevinharrington oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT richardvile oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT alanmelcher oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus AT hardevpandha oncolyticimmunotherapyforbladdercancerusingcoxsackiea21virus |